Abbott Laboratories disclosed 12‑month clinical outcomes for its Volt Pulsed Field Ablation (PFA) System at the AF Symposium in Boston. The VOLT‑AF Global IDE study showed an 84.2% freedom from documented rhythm recurrence in patients with paroxysmal atrial fibrillation and a 68% freedom from recurrence in those with persistent atrial fibrillation, the highest rates among competing PFA products.
The company also presented 6‑month data for its TactiFlex Duo Ablation Catheter, Sensor‑Enabled, from the FOCALFLEX Global CE Mark trial. The dual‑energy catheter achieved an 81% success rate in freedom from rhythm recurrence in paroxysmal atrial fibrillation patients, while patient‑reported quality‑of‑life scores improved from 64.4 to 86.4 on a 100‑point scale.
These results reinforce Abbott’s leadership in minimally invasive atrial fibrillation therapy. The high freedom‑from‑recurrence rates suggest that both devices could accelerate adoption in the U.S. and European markets, where Abbott already holds FDA approval for Volt PFA and CE Mark approval for TactiFlex Duo. The data also support the company’s strategy to expand market share against rivals such as Medtronic, Johnson & Johnson, and Boston Scientific, and to enhance reimbursement prospects for next‑generation AF devices.
Abbott’s broader electrophysiology business has recently reported strong financial performance, with Q4 2025 sales growth and a 2026 guidance that projects organic revenue growth of 6.5%–7.5% and adjusted diluted EPS of $5.55–$5.80. While the clinical data announcement is separate from the earnings release, it provides additional evidence of the company’s product pipeline strength and may influence future sales momentum in the AF segment.
The data presentation underscores Abbott’s commitment to advancing PFA technology, which offers a more targeted ablation approach compared to traditional radiofrequency methods. By demonstrating superior freedom‑from‑recurrence rates, Abbott positions its devices as attractive options for clinicians seeking durable outcomes, potentially translating into increased market penetration and long‑term revenue growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.